Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

29 publications found

  1. Carlini BH, Kellum LB, Garrett SB, Williams JR. Cannabis-related problems, adverse events, clinical experiences and barriers to intervening: Perspectives of health care providers in Washington State. Substance Use & Addiction Journal 2026;47(3):852-863. [doi: 10.1177/29767342261426116] PMID: 41910114
  2. Carlini BH, Williams JR, Garrett SB, Hammond D. People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: A study in WA State, USA. Community Mental Health Journal 2026;62:889-895. [doi: 10.1007/s10597-025-01579-1]
  3. Garrett SB, Williams J, Carlini BH, Hammond D. Cannabis consumer patterns, adverse events, and cannabis risk beliefs: A latent profile analysis in WA State. Drug and Alcohol Dependence 2025;273:112728. [doi: 10.1016/j.drugalcdep.2025.112728]
  4. Harwick RM, Carlini BH, Williams JR. Food hardship as a strong predictor of tobacco and cannabis use among youth in WA state. Children and Youth Services Review 2024;157:107427. [doi: 10.1016/j.childyouth.2023.107427]
  5. Carlini BH, Harwick RH, Williams JR. Language Matters: Cannabis and Tobacco Use Among Youth of Diverse Racial/Ethnic Backgrounds. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, July 2024.
  6. Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S. Community-based medications first for opioid use disorder – Care utilization and mortality outcomes. Substance Abuse and Rehabilitation 2024;15:173-183 [doi: 10.2147/sar.s475807]
  7. Banta-Green CJ, Owens MD, Williams JR, Sears JM, Floyd AS, Williams-Gilbert W, Kingston S. Community Based Medications First for Opioid Use Disorder – Care Utilization and Mortality Outcomes. Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Denver, CO, June 2023
  8. Banta-Green CJ, Owens MD, Williams JR, Sears JM, Floyd AS, Williams-Gilbert W, Kingston S. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State. Addiction Science & Clinical Practice 2022;17:34. [doi: 10.1186/s13722-022-00315-4] PMID: 35799210 PMCID: PMC9261214
  9. Banta-Green C, Williams J. Overdose Deaths Involving Pharmaceutical Opioids in Washington State from 2010-2021. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, November 2022
  10. Banta-Green CJ, Williams J. Dramatic Increases in Opioid Overdose Deaths Due to Fentanyl Among Young People in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, December 2021
  11. Banta-Green CJ, Tinsley J, Hood J, Glick S, Finegood B, Williams J, Smith R. National Drug Early Warning System (NDEWS) Seattle Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2020. College Park, MD: Center for Substance Abuse Research, National Institute on Drug Abuse, August 2020, 18p.
  12. Hartzler B, Carlini BH, Williams JR, Crane HM, Geng EH, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Napravnik S, Rodriguez B, Donovan DM. Marijuana as a risk factor for discontinuity of care among persons living with HIV/AIDS. [conference abstract]. Cannabis 2020;3(1):93
  13. Banta-Green CJ, Williams JR, Sears JM, Floyd AS, Tsui JI, Hoeft TJ. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder. Drug and Alcohol Dependence 2020;207:107799 [doi: 10.1016/J.DRUGALCDEP.2019.107799] PMID: 31865058 PMCID: PMC8085903
  14. Burgard DA, Williams JR, Westerman D, Rushing R, Carpenter R, LaRock A, Sadetsky J, Clarke J, Fryhle H, Pellman M, Banta-Green CJ. Using wastewater-based analysis to monitor the effects of legalized retail sales on cannabis consumption in Washington State, USA. Addiction 2019;114(9):1582-1590. [doi: 10.1111/add.14641] PMID: 31211480 PMCID: PMC6814135
  15. Hartzler B, Dombrowski JC, Williams JR, Crane HM, Eron JJ, Geng EH, Mathews C, Mayer KH, Moore RD, Mugavero MJ, Napravnik S, Rodriguez B, Donovan DM. Influence of substance use disorders on 2-Year HIV care retention in the United States. AIDS and Behavior 2018;22(3):742-751. [doi: 10.1007/s10461-017-1826-2] PMID: 28612213 PMCID: PMC5729068
  16. Banta-Green CJ, Williams JR, King County Community Epidemiology Workgroup. Drug Use Trends in King County, Washington, 2017. Seattle: Alcohol & Drug Abuse Institute, University of Washington, May 2018, 14 p.
  17. Williams JR, Bugard D, Banta-Green CJ. Estimating Cannabinoid Mass Sold from Noisy Cannabis Sales Data. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2018.
  18. Stoner SA, Williams JR, Newman A, Sutherland NL, Banta-Green CJ. Methamphetamine in Washington: Report to the Division of Behavioral Health and Recovery. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2018, 35p. (includes appendices)
  19. Williams JR, Banta-Green CJ. Opioid Use Estimates: Surveys Use Different Methodologies and Produce Different Estimates. Seattle : Alcohol and Drug Abuse Institute, University of Washington, December 2018, 5p.
  20. Williams JR. Cannabis Use: Impact in Washington State. Seattle : Alcohol and Drug Abuse Institute, University of Washington, June 2017